Unknown

Dataset Information

0

Glycerol monolaurate prevents mucosal SIV transmission.


ABSTRACT: Although there has been great progress in treating human immunodeficiency virus 1 (HIV-1) infection, preventing transmission has thus far proven an elusive goal. Indeed, recent trials of a candidate vaccine and microbicide have been disappointing, both for want of efficacy and concerns about increased rates of transmission. Nonetheless, studies of vaginal transmission in the simian immunodeficiency virus (SIV)-rhesus macaque (Macacca mulatta) model point to opportunities at the earliest stages of infection in which a vaccine or microbicide might be protective, by limiting the expansion of infected founder populations at the portal of entry. Here we show in this SIV-macaque model, that an outside-in endocervical mucosal signalling system, involving MIP-3alpha (also known as CCL20), plasmacytoid dendritic cells and CCR5(+ )cell-attracting chemokines produced by these cells, in combination with the innate immune and inflammatory responses to infection in both cervix and vagina, recruits CD4(+) T cells to fuel this obligate expansion. We then show that glycerol monolaurate-a widely used antimicrobial compound with inhibitory activity against the production of MIP-3alpha and other proinflammatory cytokines-can inhibit mucosal signalling and the innate and inflammatory response to HIV-1 and SIV in vitro, and in vivo it can protect rhesus macaques from acute infection despite repeated intra-vaginal exposure to high doses of SIV. This new approach, plausibly linked to interfering with innate host responses that recruit the target cells necessary to establish systemic infection, opens a promising new avenue for the development of effective interventions to block HIV-1 mucosal transmission.

SUBMITTER: Li Q 

PROVIDER: S-EPMC2785041 | biostudies-literature | 2009 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications


Although there has been great progress in treating human immunodeficiency virus 1 (HIV-1) infection, preventing transmission has thus far proven an elusive goal. Indeed, recent trials of a candidate vaccine and microbicide have been disappointing, both for want of efficacy and concerns about increased rates of transmission. Nonetheless, studies of vaginal transmission in the simian immunodeficiency virus (SIV)-rhesus macaque (Macacca mulatta) model point to opportunities at the earliest stages o  ...[more]

Similar Datasets

| S-EPMC4808581 | biostudies-literature
| S-EPMC9355977 | biostudies-literature
| S-EPMC8076190 | biostudies-literature
| S-EPMC9307562 | biostudies-literature
| S-EPMC4960522 | biostudies-literature
| S-EPMC9413120 | biostudies-literature
| S-EPMC6048963 | biostudies-literature
| S-EPMC2906837 | biostudies-literature
| S-EPMC7662997 | biostudies-literature
| S-EPMC9784515 | biostudies-literature